Ascendis Pharma A/S

ASND

Biotechnology · Healthcare

Price

$261.00

+1.20 (+0.46%)

Market Cap

$16.21B

Exchange

NASDAQ

Winston Score

Winston is serious

Below-average fundamentals — multiple weak pillars.

Share count rising — dilution

+10.7% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 54.8M (2021) → 60.6M (2025)

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia. In addition, the company develops TransCon toll like receptors 7/8 agonist for intratum

Winston Score History

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

+148.3% YoY

YoY Growth Rate

Revenue accelerating

EPS Growth

+756.3% YoY

YoY Growth Rate

EPS growth accelerating

R&D Spend

$284M/ year

↓ Declining (-8% vs prior year)

41.0% of revenue

2.3x the sector average (18%)

R&D spend declining — could signal cost-cutting or efficiency

Insider Activity

0.9%ownership

Relatively low insider ownership

Cash Runway

~9 years

$573M cash & investments

Quarterly Free Cash Flow

↑ Burn rate improving

$573M cash & investments at current burn rate

Revenue accelerating

Ascendis Pharma A/S grew revenue 148% year-over-year and the growth rate is speeding up. That's the kind of momentum growth investors look for — the question is whether margins can follow.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin

91.4%

Premium pricing power — 91.4% gross margin

Operating Margin

10.1%

Modest — 10.1% operating margin

ROCE

1.8%

Weak — 1.8% return on capital

ROIC between 0% and 5%. They earn a few cents back per dollar invested in the business.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY

+135.3%

Fast-growing sales (135.3% YoY)

EPS YoY

N/A

—

Data not available

EPS Consistency

2/8 quarters

Earnings rarely grow — volatile business

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion

11%

Weak — only 11% of profit becomes cash

FCF Margin

4.9%

Thin free cash flow (4.9%)

FCF margin between 0% and 10%. Some cash from sales, but not a lot.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity

1.84

Elevated debt (1.84)

Interest Cover

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)

31.9x

Pricey — P/E 31.9

P/E above the market average. People are paying up for expected growth.

P/E vs Forward

+13.8

GROWING

Earnings expected to grow meaningfully — cheaper on forward P/E (31.9 → 18.1)

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial